Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fimasartan + amlodipine + rosuvastatin (Dongwha Pharmaceutical Co., Ltd.)
- Development stage
- Unknown
- Lead developer
- Boryung
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DW6014 is a fixed-dose triple combination therapy developed by Dongwha Pharmaceutical for the management of patients suffering from both essential hypertension and primary hypercholesterolemia. The drug combines three established active pharmaceutical ingredients: fimasartan, an angiotensin II receptor antagonist (ARB) that promotes vasodilation; amlodipine, a dihydropyridine calcium channel blocker (CCB) that reduces peripheral vascular resistance; and rosuvastatin, a statin that inhibits HMG-CoA reductase to lower LDL cholesterol levels. By consolidating these three mechanisms into a single oral tablet, DW6014 is designed to simplify complex medication regimens, thereby improving patient adherence and achieving better therapeutic outcomes in the co-management of cardiovascular risk factors. It is currently in late-stage clinical development in South Korea as part of Dongwha's 'Improved Drug' (Incremental Modified Drug) portfolio.
- Other names
- fimasartan/amlodipine/rosuvastatin
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on fimasartan + amlodipine + rosuvastatin (Dongwha Pharmaceutical Co., Ltd.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fimasartan + amlodipine + rosuvastatin (Dongwha Pharmaceutical Co., Ltd.).